Evidence map›Paper›PMID 42536686›Full record

ArticlePLoS pathogens2026

The residue 86 of the Getah virus E2 glycoprotein mediates both glycosaminoglycan- and LDLR-dependent infection.

Xiangshu Qiu, Rongguang Lu, Jiaxin Tian, He Zhang, Jiyong Zhou, Mengsi Sun, Xinyu Cao, Xiangyu Zhu, Bocheng Liu, Qihui Yu and 5 more

Abstract read
In one paragraph

Article in PLoS pathogens, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Xiangshu QiuMOA Key Laboratory of Animal Virology, Zhejiang University Center for Veterinary Sciences, Hangzhou, China.
Rongguang LuInstitute of Infectious Diseases, Shenzhen Bay Laboratory, Shenzhen, China.
Jiaxin TianMOA Key Laboratory of Animal Virology, Zhejiang University Center for Veterinary Sciences, Hangzhou, China.
He ZhangState Key Laboratory of Pathogen and Biosecurity, Changchun Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Changchun, China.
Jiyong ZhouMOA Key Laboratory of Animal Virology, Zhejiang University Center for Veterinary Sciences, Hangzhou, China.
Mengsi SunInstitute of Infectious Diseases, Shenzhen Bay Laboratory, Shenzhen, China.
Xinyu CaoState Key Laboratory of Pathogen and Biosecurity, Changchun Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Changchun, China.
Xiangyu ZhuState Key Laboratory of Pathogen and Biosecurity, Changchun Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Changchun, China.
Bocheng LiuState Key Laboratory of Pathogen and Biosecurity, Changchun Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Changchun, China.
Qihui YuState Key Laboratory of Pathogen and Biosecurity, Changchun Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Changchun, China.
Yuanyuan LiState Key Laboratory for Diagnosis and Treatment of Severe Zoonotic Infectious Diseases, Key Laboratory for Zoonosis Research of the Ministry of Education, Institute of Zoonosis, and College of Veterinary Medicine, Jilin University, Changchun, China.
Hualei WangState Key Laboratory for Diagnosis and Treatment of Severe Zoonotic Infectious Diseases, Key Laboratory for Zoonosis Research of the Ministry of Education, Institute of Zoonosis, and College of Veterinary Medicine, Jilin University, Changchun, China.
Ningyi JinMOA Key Laboratory of Animal Virology, Zhejiang University Center for Veterinary Sciences, Hangzhou, China.
Huijun LuMOA Key Laboratory of Animal Virology, Zhejiang University Center for Veterinary Sciences, Hangzhou, China.ORCID 0000-0003-4532-4466
Ning ShiState Key Laboratory of Pathogen and Biosecurity, Changchun Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Changchun, China.

Funding

China Postdoctoral Science FoundationNational Key Research and Development Program of ChinaScience and Technology Development Program of Jilin Province
6 · The paper itself

Abstract

Getah virus (GETV), a mosquito-borne alphavirus, poses an emerging threat to public health with its increasingly broad host spectrum. While glycosaminoglycans (GAGs) serve as critical attachment factors for many alphaviruses and the low-density lipoprotein receptor (LDLR) facilitates the cellular entry of several members, the precise viral determinants governing these interactions and their implications for viral virulence remain poorly defined. Here, we introduced an H86Y substitution, a potential adaptive mutation site, within the E2 glycoprotein of GETV using reverse genetics. The H86Y mutant replicated more efficiently in mosquito C6/36 cells but was consistently attenuated across several mammalian cell lines. In susceptible mouse models, H86Y infection led to reduced viral loads, milder histopathology, and lower inflammatory responses compared with the parental virus, yet still elicited robust protective immunity in adult mice. Mechanistically, a series of functional assays, including infection in GAG-deficient cells, decoy inhibition, co-immunoprecipitation, receptor overexpression and knockdown, and biolayer interferometry, demonstrated that the residue 86 in E2 glycoprotein is a critical determinant for GETV binding to both GAGs and LDLR. The H86Y mutation concurrently reduces these interactions, contributing the impairment of virus attachment and entry into mammalian cells. Furthermore, the GAG-binding site functionally overlaps with the LDLR interaction interface. In LDLR-deficient suckling mice, the impaired replication of H86Y persisted in examined tissues. However, pre-treatment with heparinase nearly completely eliminated this attenuation phenotype, further confirming that LDLR and GAG are the key host factors mediating attenuation phenotype for H86Y. In summary, the residue 86 of the GETV E2 glycoprotein represents a determinant of viral virulence, and an H86Y mutation attenuates GAGs and LDLR-dependent infection, providing mechanistic insights into alphavirus-host interactions and a potential target for antiviral and vaccine development.

Indexed as

AlphavirusAlphavirus InfectionsGlycosaminoglycansReceptors, LDLViral Envelope ProteinsAnimalsFemaleHumansMiceGlycosaminoglycansReceptors, LDLViral Envelope Proteins

Identifiers

PMID42536686
PMCPMC13426916

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.